Markets
BSE See NSE See 39,338.90
226.16 (0.58%)
collapse Related Readings collapse

In The Pink Of Health - Twilight Litaka Pharma

By Kaustubh Ghotikar | 9/27/2010 5:06 PM Monday

In a market which is marching briskly to test its all-time highs, if you come across a scrip that is growing at three-year CAGR of 34 per cent and 32 per cent in the topline and bottomline and yet available at a PE of 9.6x of its trailing numbers, it does make sense to pursue it further. We are talking about Twilight Litaka Pharma (TLP) and this is exactly what we did once it was short-listed for our analysis column. In a bid to get more insights on this pharma company we had a tete-a-tete with Gopal Ramourti, Managing Director, Twilight Litaka Pharma (TLPL) at their Andheri headquarters.

The initial discussion itself threw up some interesting points in the course of which Ramourti informed us that the broader business segments for the company included contract research and manufacturing services (CRAMS), domestic formulations, and exports. He further stated that the CRAMS segment has been the biggest contributor in terms of revenues and accounts for 57 per cent of the sales of the company. “TLPL has been involved in contract manufacturing for large companies in the pharmaceutical space which includes Novartis, Wockhardt, Cipla, Lupin, Serum, Pfizer, Herbalife, etc,” Ramourti informed.  However, with top client contribution at 8-10 per cent, the segment is fairly de-risked and none of the revenue is skewed in favour of any single client. The company manufactures drugs and formulations in the form of tablets, ointments, liquids, capsules, etc. and focuses on categories such as anti-inflammatory, anti-asthmatic, antibiotics, vitamins, antioxidants, etc. That apart, TLPL has also been working on the food and nutrition space over the last 12 years. However, general medicine forms 80 per cent of the total CRAMS revenues while the balance 20 per cent is derived from food and nutrition.

As the discussion moved forward, Ramourti introduced us to the domestic formulation business. This segment contributes up to 35 per cent of the total revenue and has five divisions. This includes Centrum (35-40 per cent to segment revenue) and Nucleus (25-30 per cent) which together focus on servicing pediatricians, physicians, surgeons, and orthopedic surgeons. It has a number of life-saving antibiotics used in surgeries and ICUs. The company’s Nutra division (10 per cent) is exclusively devoted to nutritional therapy that helps improve the quality of life.

 

Find More Articles on: Fundamental Picks, DSIJ Magazine, Analysis, Stock Recommendations

«« First « Previous |1 2 3 | Last ››
news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.